EyePoint Inc (EYPT)

Industry Biotechnology


This stock can be held in an Investment ISA and an Investment Account
Sell

$13.10

Buy

$13.79

arrow-up$0.14 (+1.06%)

Prices updated at 01 May 2026, 22:29 EDT
| Prices minimum 15 mins delay
|
Prices in USD

EyePoint Pharmaceuticals Inc, formerly pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Goran A. Ando, M.D.
CEO
Dr. Jay S. Duker, M.D.
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
214
Head office
480 Pleasant Street
Watertown
United States
02472
mobile
+1 833 393-7646
letter
-

Key personnel

Salary
Mr. Fred Hassan
Independent Director
0.05m
Ms. Nancy S. Lurker
Vice Chairman of the Board
0.08m
Ms. Wendy F. DiCicco
Independent Director
0.08m
Mr. George O. Elston
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
0.53m
Dr. John B. Landis, PhD
Director
0.05m
Ms. Karen Zaderej
Independent Director
0.07m
Dr. Jay S. Duker, M.D.
Director, President and Chief Executive Officer
0.70m
Dr. Goran A. Ando, M.D.
Chairman of the Board
0.10m
Mr. Stuart M. Duty
Independent Director
0.06m
Dr. Ramiro Ribeiro, M.D.,PhD
Chief Medical Officer
0.51m
Dr. Reginald J. Sanders, M.D.
Director
0.05m

Top 5 shareholders

No. of shares
Cormorant Asset Management, LLC8,265,000
Suvretta Capital Management, LLC7,827,685
BlackRock Inc6,787,872
Franklin Advisers, Inc.6,338,600
Federated Hermes Inc6,017,433

Director dealings

Action
19 Dec 2025-
19 Dec 2025-
04 Dec 2025-
26 Nov 2025-
28 Nov 2025-
11 Nov 2025-
19 Sep 2025-
19 Sep 2025-
11 Jul 2025-
11 Jul 2025-
10 Jul 2025-
10 Jul 2025-
10 Jul 2025-
10 Jul 2025-
10 Jul 2025-
02 Jul 2025-
02 Jul 2025-
02 Jul 2025-
02 Jul 2025-
02 Jul 2025-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2026 Morningstar. All rights reserved.